CO2021009379A2 - Formulaciones y métodos de la vacuna contra el norovirus - Google Patents

Formulaciones y métodos de la vacuna contra el norovirus

Info

Publication number
CO2021009379A2
CO2021009379A2 CONC2021/0009379A CO2021009379A CO2021009379A2 CO 2021009379 A2 CO2021009379 A2 CO 2021009379A2 CO 2021009379 A CO2021009379 A CO 2021009379A CO 2021009379 A2 CO2021009379 A2 CO 2021009379A2
Authority
CO
Colombia
Prior art keywords
methods
vaccine formulations
norovirus vaccine
norovirus
vaccines
Prior art date
Application number
CONC2021/0009379A
Other languages
English (en)
Spanish (es)
Inventor
Frank Baehner
Taisei Masuda
Paul Mendelman
James Sherwood
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CO2021009379A2 publication Critical patent/CO2021009379A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CONC2021/0009379A 2018-12-20 2021-07-19 Formulaciones y métodos de la vacuna contra el norovirus CO2021009379A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782733P 2018-12-20 2018-12-20
PCT/US2019/067961 WO2020132510A1 (en) 2018-12-20 2019-12-20 Norovirus vaccine formulations and methods

Publications (1)

Publication Number Publication Date
CO2021009379A2 true CO2021009379A2 (es) 2021-08-30

Family

ID=71101884

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0009379A CO2021009379A2 (es) 2018-12-20 2021-07-19 Formulaciones y métodos de la vacuna contra el norovirus

Country Status (14)

Country Link
US (1) US20220054621A1 (https=)
EP (1) EP3897712A4 (https=)
JP (1) JP2022514759A (https=)
KR (1) KR20210114941A (https=)
CN (1) CN113453711A (https=)
AR (1) AR117462A1 (https=)
AU (1) AU2019404430A1 (https=)
BR (1) BR112021012181A2 (https=)
CA (1) CA3123860A1 (https=)
CO (1) CO2021009379A2 (https=)
IL (1) IL284233A (https=)
MX (1) MX2021007502A (https=)
SG (1) SG11202106628YA (https=)
WO (1) WO2020132510A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740624B (zh) 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
EP4112074A1 (en) 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
WO2022143282A1 (zh) * 2020-12-30 2022-07-07 远大赛威信生命科学(南京)有限公司 诺如病毒病毒样颗粒、免疫组合物或试剂盒及其用途
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
WO2024202045A1 (ja) * 2023-03-31 2024-10-03 デンカ株式会社 腸管へのウイルス特異的な抗体誘導が可能なノロウイルスワクチン
WO2025076792A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Product Co., Ltd. Methods of preparing norovirus vaccine with low amounts of adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2514316T3 (es) * 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
CN104740624B (zh) * 2007-09-18 2018-04-24 武田疫苗股份有限公司 赋予针对诺如病毒的保护性免疫应答的疫苗
NO2324113T3 (https=) * 2008-08-08 2018-07-28
US20110070260A1 (en) * 2009-09-09 2011-03-24 Baric Ralph S Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use
CA2787666A1 (en) * 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
EP4112074A1 (en) * 2011-07-11 2023-01-04 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations

Also Published As

Publication number Publication date
JP2022514759A (ja) 2022-02-15
US20220054621A1 (en) 2022-02-24
SG11202106628YA (en) 2021-07-29
AU2019404430A1 (en) 2021-07-08
CN113453711A (zh) 2021-09-28
WO2020132510A1 (en) 2020-06-25
KR20210114941A (ko) 2021-09-24
BR112021012181A2 (pt) 2021-08-31
CA3123860A1 (en) 2020-06-25
AR117462A1 (es) 2021-08-04
IL284233A (en) 2021-08-31
EP3897712A4 (en) 2022-08-31
MX2021007502A (es) 2021-10-13
EP3897712A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
CO2021009379A2 (es) Formulaciones y métodos de la vacuna contra el norovirus
EP4366768A4 (en) Pan-human coronavirus vaccines
BR112017001796A2 (pt) composições de flagelina e seus usos
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
MX2018014573A (es) Vacuna contra el virus del zika.
PL3585803T3 (pl) Formulacje skoniugowanych szczepionek przeciwko pneumokokom
EP3668541A4 (en) FORMULATIONS FOR PNEUMOCOCCAL CONJUGATE VACCINE
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
UY37563A (es) Aislados de bacillus y usos de los mismos
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
MX2018007198A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
DK3197489T3 (da) Fremgangsmåder og sammensætninger til at fremkalde beskyttende immunitet over for human immundefekt virusinfektion
MX2023012390A (es) Vacunacion con particulas de replicon y adyuvante oleoso.
MX381211B (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
MX2020011712A (es) Vacunas de nanoparticulas multivalentes contra la influenza.
CL2015002273A1 (es) Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o una infección limitante por eimeria
MX2018016306A (es) Virus de enteritis de pato y usos del mismo.
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
CO2018010359A2 (es) Constructos de alfavirus vivo atenuado y métodos y usos de los mismos
MX381252B (es) Virus de la enteritis del pato y usos del mismo.
IL313254A (en) Coronavirus vaccine formulations
CL2018000253A1 (es) Respuesta inmunitaria potenciada de las especies porcinas